Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) has received an average rating of “Buy” from the ten ratings firms that are currently covering the company. One analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $44.67.

A number of research analysts recently issued reports on ALDR shares. Jefferies Group reiterated a “buy” rating on shares of Alder BioPharmaceuticals in a report on Tuesday, August 23rd. JPMorgan Chase & Co. started coverage on shares of Alder BioPharmaceuticals in a report on Tuesday, September 13th. They issued an “overweight” rating and a $40.00 price objective for the company. Zacks Investment Research upgraded shares of Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $38.00 price objective for the company in a report on Tuesday, September 27th. Brean Capital began coverage on shares of Alder BioPharmaceuticals in a report on Friday, September 30th. They set a “buy” rating and a $45.00 price target for the company. Finally, Piper Jaffray Cos. began coverage on shares of Alder BioPharmaceuticals in a report on Monday, October 31st. They set an “overweight” rating and a $47.00 price target for the company.

Shares of Alder BioPharmaceuticals (NASDAQ:ALDR) traded down 8.02% during mid-day trading on Monday, hitting $24.65. 660,969 shares of the stock were exchanged. The stock’s 50 day moving average price is $28.00 and its 200-day moving average price is $29.05. Alder BioPharmaceuticals has a 12-month low of $15.82 and a 12-month high of $39.43. The stock’s market capitalization is $1.24 billion.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.15. During the same quarter in the prior year, the business posted ($0.62) earnings per share. On average, equities research analysts expect that Alder BioPharmaceuticals will post ($3.13) EPS for the current fiscal year.

In other news, insider Randall C. Schatzman sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $32.48, for a total transaction of $324,800.00. Following the completion of the sale, the insider now owns 124,768 shares of the company’s stock, valued at approximately $4,052,464.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Jeffrey T. L. Smith sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of $32.49, for a total transaction of $97,470.00. Following the sale, the vice president now directly owns 3,000 shares of the company’s stock, valued at approximately $97,470. The disclosure for this sale can be found here. Insiders own 11.50% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Ameriprise Financial Inc. increased its stake in shares of Alder BioPharmaceuticals by 8.4% in the second quarter. Ameriprise Financial Inc. now owns 233,634 shares of the biopharmaceutical company’s stock valued at $5,832,000 after buying an additional 18,103 shares during the period. Neuberger Berman Group LLC acquired a new stake in Alder BioPharmaceuticals during the second quarter valued at about $499,000. State Board of Administration of Florida Retirement System increased its stake in Alder BioPharmaceuticals by 20.4% in the second quarter. State Board of Administration of Florida Retirement System now owns 20,375 shares of the biopharmaceutical company’s stock valued at $509,000 after buying an additional 3,453 shares during the last quarter. M&T Bank Corp acquired a new stake in Alder BioPharmaceuticals during the second quarter valued at about $265,000. Finally, DekaBank Deutsche Girozentrale increased its stake in Alder BioPharmaceuticals by 35.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 25,400 shares of the biopharmaceutical company’s stock valued at $618,000 after buying an additional 6,600 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This news story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was stolen and republished in violation of United States and international copyright and trademark law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2016/11/28/alder-biopharmaceuticals-inc-aldr-receives-consensus-recommendation-of-buy-from-analysts.html.

Alder BioPharmaceuticals Company Profile

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

5 Day Chart for NASDAQ:ALDR

Receive News & Stock Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.